Generic Medicine Info
Should be taken with food.
Hypersensitivity (including asthma) to ibuprofen or other NSAIDs. History of gastrointestinal bleeding, perforation, or ulceration related to NSAID therapy. Gastrointestinal ulceration, perforation or haemorrhage. Severe cardiac failure or patients undergoing coronary artery bypass graft surgery. Severe renal or hepatic impairment. Pregnancy (3rd trimester).
Special Precautions
Patient with CV disease or risk factors of (e.g. CHF, ischaemic heart disease, CVA, hypertension, hyperlipidaemia, diabetes mellitus), bleeding disorders, SLE, mixed connective tissue disorders, porphyria. Surgery. Hepatic and renal impairment. Elderly, children (especially premature neonates with risk factors for infection and infants with increased bilirubin levels). Pregnancy (1st-2nd trimester) and lactation. Concomitant use of other NSAIDs, antiplatelets, anticoagulants. Not for prolonged usage. Patient Counselling This drug may cause dizziness, drowsiness or blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor CBC, occult blood loss, K levels, LFTs and renal function; signs and symptoms of ophthalmic-related reactions.
Adverse Reactions
Significant: Anaphylactoid reactions, risk of hyperkalaemia, oedema, HTN, liver function abnormalities, anaemia, blurred vision, scotomata, changes in colour vision. Rarely, severe blood dyscrasias (e.g. agranulocytosis, thrombocytopenia, aplastic anaemia). Ear and labyrinth disorders: Tinnitus. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, heartburn, abdominal pain; enterocolitis (IV). General disorders and administration site conditions: Fluid retention. Infections and infestations: Sepsis (IV). Injury, poisoning and procedural complications: Injection site reactions. Investigations: Increased BUN (IV). Metabolism and nutrition disorders: Decreased appetite; hypoalbuminemia, hypoglycaemia, hypocalcaemia, hypokalaemia, hypernatraemia, adrenal insufficiency (IV). Nervous system disorders: Headache, dizziness; intraventricular haemorrhage (IV). Psychiatric disorders: Nervousness. Renal and urinary disorders: Haematuria, UTI. Respiratory, thoracic and mediastinal disorders: Apnoea, cough, respiratory infection. Skin and subcutaneous tissue disorders: Rashes, pruritus; skin irritation (IV).
Potentially Fatal: CV thrombotic events (e.g. MI, stroke), gastrointestinal ulceration, perforation or haemorrhage; rarely, hepatotoxicity (e.g. fulminant hepatitis, hepatic necrosis or failure), Stevens-Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis.
Drug Interactions
Increased risk of gastrointestinal ulceration, perforation or haemorrhage with other NSAIDs (e.g. aspirin), antiplatelets, anticoagulants (e.g. warfarin), corticosteroids, SSRIs. Increased risk of hyperkalaemia and renal toxicity with ciclosporin, tacrolimus. Increased levels and risk of toxicity with lithium, methotrexate. May decrease antihypertensive effect of ACE inhibitors, angiotensin II receptor antagonist; natriuretic effect of diuretics.
CIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) / Other Cardiovascular Drugs
ATC Classification
G02CC01 - ibuprofen ; Belongs to the class of antiinflammatory products for vaginal administration used in the treatment and prevention of inflammation.
M02AA13 - ibuprofen ; Belongs to the class of non-steroidal antiinflammatory preparations for topical use. Used in the treatment of joint and muscular pains.
M01AE01 - ibuprofen ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.
C01EB16 - ibuprofen ; Belongs to the class of other cardiac preparations.
R02AX02 - ibuprofen ; Belongs to the class of other throat preparations.
Disclaimer: This information is independently developed by CIMS based on ibuprofen from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in